Detection of Specific Glycan Moieties on the Cell Surface

细胞表面特定聚糖部分的检测

基本信息

  • 批准号:
    8349512
  • 负责人:
  • 金额:
    $ 18.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

In the present work, we have used mutant galactosyltransferases previously developed in our lab to detect GlcNAc and LacNAc on the surface of human cervical cancer cells (HeLa). The mutant enzymes have a cavity that has been carved in the donor site to accommodate UDP-Gal with a chemical handle at C2, such as azide (GalNAz) or keto group (C2-keto-Gal). The chemical handles are used for conjugation with fluoroprobes or biotin carrying bio-orthogonal group to detect the acceptor GlcNAc or LacNAc. We are using a double mutant of beta-1-4-galactosyltransferase-1 (beta-1,4GalT-1), Y289L-M344H-beta-1,4Gal-T1, that transfers GalNAz to GlcNAc in the presence of Mg2+, for detecting GlcNAc residue on the surface of live cells. The Tyr289Leu (Y289L) mutation allows the carving of the cavity to accommodate UDP-GalNAz, whereas the second mutation, Met344His (M344H), located in the enzyme's metal binding site, changes the metal cofactor requirement from Mn2+ to Mg2+. Since Mn2+, in contrast to Mg2+, is toxic to the cells, the Mg2+ dependent enzyme is very useful for labeling of live cells. Detection is investigated using confocal microscopy and flow cytometry. Green membrane fluorescent signal (corresponding to DIBO-Alexa 488) is detected on the HeLa cells only when cells are pre-treated with sialidase and galactosidase enzymes, indicating that glycans with free GlcNAc residues are not abundant on the surface of HeLa cells. The LacNAc moiety on the cell surface is detected using alpha-1,3-galactosyltransferase (alpha-1,3GalT) mutant enzyme, alpha-1,3GalT-280AGG282 , which transfers GalNAz or C2-keto-Gal to N-acetyl-lactosamine (LacNAc). The GalNAz or C2-keto-Gal labeled glycans are coupled with alkyne- or aminooxy-biotin, respectively. On fixed cells, coupled biotin is detected with streptavidin-Alexa Fluor 488. On extracts, coupled biotin is detected with streptavidin-HRP. Fluorescent signal is detected on cell membranes, as opposed to control samples where no UDP-GalNAz is present. Cells that are pre-treated with sialidase, increased the signal intensity, indicating that the density of exposed LacNAc residues is augmented by the removal of sialic acid. Similar results are obtained by Western Blot analysis. In conclusion, the use of Y289L-M344H-beta-1,4Gal-T1 and alpha-1,3GalT-280AGG282 enzymes, together with other glycosyltransferases currently being produced in our lab, could be powerful tools to investigate the cells glycophenotype with high specificity.
在目前的工作中,我们使用我们实验室以前开发的突变的半乳糖基转移酶来检测人宫颈癌细胞(HeLa)表面的GlcNAc和LacNAc。突变酶在供体部位有一个空腔,以适应在C2处有化学句柄的UDP-Gal,如叠氮(GalNAz)或酮基(C2-keto-Gal)。所述化学手柄用于与荧光探针或携带生物素的生物正交基偶联以检测受体GlcNAc或LacNAc。我们使用β-1-4-半乳糖基转移酶-1(β-1,4GalT-1)的双突变体Y289L-M344H-β-1,4Gal-T1,在镁离子存在的情况下将GalNAz转移到GlcNAc,用于检测活细胞表面的GlcNAc残基。Tyr289Leu(Y289L)突变允许雕刻空洞以容纳UDP-GalNAz,而第二个突变Met344His(M344H)位于酶的金属结合部位,将金属辅因子需求从Mn2+改变为Mg2+。由于与镁离子相比,锰离子对细胞有毒性,因此镁离子依赖酶对活细胞的标记是非常有用的。使用共聚焦显微镜和流式细胞术进行检测。只有在唾液酸酶和半乳糖苷酶处理的HeLa细胞上才能检测到绿膜荧光信号(对应于Dibo-Alexa 488),这表明HeLa细胞表面没有丰富的含有游离GlcNAc残基的多糖。用α-1,3-半乳糖基转移酶(α-1,3GalT)突变酶α-1,3GalT-280AGG282检测细胞表面的LacNAc部分,该酶将GalNAz或C2-keto-Gal转移到N-乙酰乳糖胺(LacNAc)。GalNAz或C2-keto-Gal标记的多糖分别与炔-生物素或氨氧基-生物素偶联。在固定细胞上,用链霉亲和素-Alexa荧光素488检测偶联生物素。在提取物上,用链霉亲和素-辣根过氧化物酶检测偶联生物素。在细胞膜上检测到荧光信号,而不是对照样品中不存在UDP-GalNAz。用唾液酸酶预处理的细胞,信号强度增加,表明暴露的LacNAc残基的密度通过唾液酸的去除而增加。Western Blot分析也得到了类似的结果。总之,Y289L-M344H-β-1,4Gal-T1和α-1,3GalT-280AGG282酶与本实验室目前正在生产的其他糖基转移酶相结合,可以作为研究细胞高特异性糖表型的有力工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pradman K Qasba其他文献

Pradman K Qasba的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pradman K Qasba', 18)}}的其他基金

Structural Studies and 3D Structure Determination of Recombinant <FONT FACE=symb
重组体的结构研究和 3D 结构测定 <FONT FACE=symb
  • 批准号:
    6433157
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Oligosaccharide Interactions with Proteins
低聚糖与蛋白质的相互作用
  • 批准号:
    6559116
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Oligosaccharide substrate interactions with beta-1,4-Ga
寡糖底物与 beta-1,4-Ga 的相互作用
  • 批准号:
    6944635
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Utilizing Glycosyltransferases for Bioconjugation
利用糖基转移酶进行生物共轭
  • 批准号:
    8552799
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Oligosaccharide substrate interactions with beta-1,4-Gal
寡糖底物与 β-1,4-Gal 的相互作用
  • 批准号:
    7291793
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Oligosaccharide Substrate and Inhibitor Interactions with beta-1,4-Gal-T1
寡糖底物和抑制剂与 β-1,4-Gal-T1 的相互作用
  • 批准号:
    7965207
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Oligosaccharide Substrate and Inhibitor Interactions with beta-1,4-Gal-T1
寡糖底物和抑制剂与 β-1,4-Gal-T1 的相互作用
  • 批准号:
    7732974
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Using Glycosyltransferases for Conjugation of Single-Chain Antibodies and Lipids
使用糖基转移酶缀合单链抗体和脂质
  • 批准号:
    8157471
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
PRINCIPALS OF CONFORMATIONAL ANALYSIS OF CARBOHYDRATES - A TEXT BOOK
碳水化合物构象分析原理 - 教科书
  • 批准号:
    6289310
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:
Structure-Function Studies and Design of Novel Glycosyltransferases
新型糖基转移酶的结构功能研究和设计
  • 批准号:
    7965164
  • 财政年份:
  • 资助金额:
    $ 18.95万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 18.95万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 18.95万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 18.95万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.95万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 18.95万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 18.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 18.95万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 18.95万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 18.95万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 18.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了